Industry Outlook
The genital herpes treatment drugs market will be featuring magnificent growth at a compounded annual growth rate (CAGR) of 4.9% during the forecast period from 2018 to 2026. According to the latest research citing’s published by World Health Organization (WHO), approximately two-thirds of the global population under 50 years of age is infected with herpes simplex virus type 1 (HSV-1). Genital herpes is contagious and transmitted via the vaginal and anal route. It is important for any individual to visit health clinic when symptoms such as small blisters around thigh, genital, or anal region are visible. Burning sensation and pain during micturition is also an early symptom related to genital herpes infection.
The product pipeline is strong with drugs such as GEN-003 a therapeutic vaccine developed by Genocea Biosciences, Inc. is currently under phase 3 clinical trial studies with promising result in reduction of genital lesions. Vical, Inc. is developing VCL-HB01 a therapeutic vaccine which is showcasing excellent results in the treatment of lesion recurrence.
Market Synopsis
Get a sample copy for more information
"Excellent pharmacodynamic and pharmacokinetic profile makes acyclovir the first line therapeutic drug for the treatment for genital herpes"
Acyclovir is currently dominating the drug class segment for genital herpes treatment drugs market. The key attributes contributing towards the dominance of acyclovir are excellent pharmacodynamic and pharmacokinetic parameters. Clinical studies have fortified the facts that acyclovir is safe, well tolerated in patients suffering with genital herpes infection. It is the first line drug therapy due to its ability to inhibit and inactivate HSV specific DNA polymerase to prevent viral DNA synthesis without causing any harm to normal cellular process. The recommended dose is 200 mg five times daily for 10 days. Famciclovir will be the fastest growing antiviral drug during the forecast period 2018 to 2026. Improved bioavailability of famciclovir is useful in the suppression of recurrent genital herpes infection in immunocompromised patients.
Get a sample copy for more information
"Rising prevalence of genital herpes drive the market growth in North America"
North America is leading the regional segment for genital herpes treatment drugs market. According to Center for Disease Control and Prevention (CDC) statistics genital herpes is prevalent in every sixth person aged between 14 to 49 years. The major factors influencing the market growth in North America are rising prevalence of genital herpes and developed diagnostic centers resulting in early diagnosis and medical intervention for treating genital herpes. In Europe the market is driven by factors such as existence of key players such as GlaxoSmithkline, Plc., Novartis AG, AstraZeneca, Plc., etc. and recent refugee influx from the Levant region has resulted in a steep increase in the genital herpes infection. Asia Pacific is set to become the fastest growing regional market during the forecast period on account of rising public health awareness regarding sexually transmitted disease, proactive government policies in curbing the spread of genital herpes infection and presence of huge generic drugs market employed for treatment.
Get a sample copy for more information
Historical & Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
The market is sub-segmented by drug class and geographical segment.
| ATTRIBUTE |
DETAILS |
| Research Period |
2016-2026 |
| Base Year |
2017 |
| Forecast Period |
2018-2026 |
| Historical Year |
2016 |
| Unit |
USD Million |
| Segmentation |
By Drug Class (2016–2026; US$ Mn)
• Acyclovir
• Famciclovir
• Valacyclovir
• Pipeline Analysis
o Phase III Drugs
GEN-003
VCL-HB01
o Tabular Representation of Drug Pipeline in Phase II and I
|
|
Geography Segment (2016–2026; US$ Mn)
• North America (United States and Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (China, Japan, Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of MEA)
|
Pharmaceutical companies providing medication for the treatment of genital herpes infection are AstraZeneca, Plc., Apotheca, Inc., Asahi Kasei Pharma Corporation, Carlsbad Technology, Inc., GlaxoSmithkline, Plc., Mylan N.V., Novartis AG., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Zydus Pharmaceuticals, Inc.
Key questions answered in this report
- Who are the key players competing in the genital herpes treatment drugs market?
- What is the latest treatment regimen followed by healthcare professionals worldwide for the treatment of genital herpes infection?
- What is the disease etiology occurring in the genital herpes infection?
- What are the drivers, opportunities and restraints pertaining to genital herpes treatment drugs market?
- What is the market performance of acyclovir in genital herpes treatment drugs market?
- What will be the compounded annual growth rate of famciclovir in genital herpes treatment drugs market?
